7-3-1-4　ⓔ文献

  1. Fisher K, Phillips C: The ecology, epidemiology and virulence of Enterococcus. Microbiology, 2009; 155: 1749–1759.

  2. Cabiltes I, Coghill S, et al: Enterococcal bacteraemia "Silent but deadly": a population-based cohort study. Intern Med J, 2019; doi: 10. 1111/imj. 14396.

  3. Sava IG, Heikins E, et al: Pathogenesis and immunity in enterococcal infections. Clin Microbiol Infect, 2010; 16: 533-540.

  4. 厚生労働省：院内感染対策サーベイランス事業．https://janis.mhlw.

go.jp/report/index.html

  1. Pinholt M, Ostergaard C, et al: Incidence, clinical characteristics and 30–day mortality of enterococcal bacteremia in Denmark 2006-2009: a population-based cohort study. Clin Microbiol Infect, 2014; 20: 145–151.

  2. Foo H, Chater M, et al. Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteremia. J Antimicrob Chemother, 2014; 69: 2252–2257.

  3. Matsumura T, Nagao M, et al: Enterococcal bacteraemia: predictive and prognostic risk factors for ampicillin resistance. Epidemiol Infect, 2018; 146: 2028–2035.

  4. Suzuki H, Hase R, et al: A 10–year profile of enterococcal bloodstream infections at a tertiary-care hospital in Japan. J Infect Chemother, 2017; 23: 390–393.

  5. Ong DS, Bonten MJ, et al: MARS consortium. Epidemiology, management, and risk-adjusted mortality of ICU-acquired enterococcal bacteremia. Clin Infect Dis, 2015; 61: 1413–1420.

  6. Petersiel N, Bitterman R, et al:β–lactam antibiotics vs. vancomycin for the early treatment of enterococcal bacteraemia: A retrospective cohort study. Int J Antimicrob Agents, 2019; 53: 761–766.

  7. Nakakura I, Sakakura K, et al: Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin–susceptible Enterococcus faecium: a single–center retrospective study. J Pharm Health Care Sci, 2019; 16: 5–8.

  8. Salgado CD, Farr BM: Outcomes associated with vancomycin–resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol, 2003; 24: 690–698.

  9. Suppli M, Aabenhus R, et al: Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobial therapy. Clin Microbiol Infect, 2011; 17: 1078–1083.

  10. JAID/JSC 感染症治療ガイド・ガイドライン作成委員会編，日本感染症学会・日本化学療法学会発行：JAID/JSC感染症治療ガイド2019，ライフサイエンス出版，2019．

  11. Keepers TR, Gomez M, et al: Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012. Infect Dis Ther, 2017; 6: 233–243.

  12. 日本循環器学会：感染性心内膜炎の予防と治療に関するガイドライン．2017年改訂版．http://www.j-circ.or.jp/guideline/pdf/JCS2017_

nakatani_h.pdf

  1. Beganovic M, Luther MK, et al: A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis. Clin Infect Dis, 2018; 67: 303–309.

  2. Araoka H, Kimura M, et al: A surveillance of high–level gentamicin resistant enterococcal bacteremia. J Infect Chemother, 2011; 17: 433–434.

  3. Jent P, Thalmann L, et al: Adjunctive gentamicin did not improve outcome of enterococcal bacteraemia in neutropenic patients: a propensity scored matched study. Infect Dis, 2019; 51: 409–416.